Aurora Cogozzo

Dr. Aurora Cogozzo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Animals
Verified
Journal Article
Open access
PDF file
VHVerena Habermaass
Verena Habermaass
FBFrancesco Bartoli
Francesco Bartoli
Eleonora GoriEleonora Gori
Eleonora Gori
Rebecca DiniRebecca Dini
Rebecca Dini
ACAurora Cogozzo
Aurora Cogozzo
Veronica MarchettiVeronica Marchetti
Veronica Marchetti
The concentrations of fecal and serum bile acids (BAs) are known to be altered in human patients with chronic liver diseases (CLDs), especially those with biliary tract involvement (BTD). Scarce literature is available regarding fecal BA modifications during canine CLDs. This study aimed to evaluate fecal BAs in canine CLDs according to different clinical and clinicopathological variables. Forty-six dogs were enrolled. Canine feces were analyzed by HPLC. Cholic Acid (CA), Chenodeoxycholic Acid (CDCA), Ursodeoxycholic Acid (UDCA), Deoxycholic Acid (DCA), and Lithocholic Acid (LCA) were measured, and primary BAs (CA + CDCA), secondary BAs (UDCA + DCA + LCA), and the primary/secondary (P/S) ratio were calculated. Primary BAs (p < 0.0001), CA (p = 0.0003), CDCA (p = 0.003), the P/S ratio (p = 0.002), and total BAs (p = 0.005) were significatively higher in BTD dogs (n = 18) compared to in non-BTD dogs (n = 28). Fecal secondary BAs did not statistically differ between BTD and non-BTD dogs. Gastrointestinal clinical signs (p = 0.028) and diarrhea (p = 0.03) were significantly more prevalent in BTD dogs compared to in non-BTD dogs, supporting the hypothesis of some pathological mechanisms assimilable to bile acid diarrhea (BAD). Our results could reflect imbalances of the fecal BA metabolism in dogs with CLDs. Further studies involving gut microbiome and metabolomic assessment are needed to better understand the possible clinical implications of BA metabolism disruption and their potential role in canine CLDs.

12 December 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
VHVerena Habermaass
Verena Habermaass
FBFrancesco Bartoli
Francesco Bartoli
Eleonora GoriEleonora Gori
Eleonora Gori
ACAurora Cogozzo
Aurora Cogozzo
alessio pierinialessio pierini
alessio pierini
Veronica MarchettiVeronica Marchetti
Veronica Marchetti
Humans with chronic biliary tract disease (CBTD) have low serum liposoluble vitamins (A, D, E). Few studies have been performed in veterinary medicine to evaluate whether vitamins vary in canine CBTD. This study aimed to compare liposoluble vitamin between CBTD and healthy dogs. A total of 84 client-owned dogs with CBTD and 50 healthy dogs were included. CBTD diagnosis was based on clinical, blood biochemistry and abdominal ultrasound. Dogs with CBTD were divided into subgroups according to their cholestasis ultrasound severity. To measure vitamin concentrations, leftover serum samples were used. The 25-hydroxyvitamin D, α-tocopherol, and retinol, respectively, vitamin D, E, and A metabolites, were measured with HPLC. Both, 25-hydroxyvitamin D and α-tocopherol were significatively lower in CBTD than in healthy dogs. In contrast, retinol was higher in CBTD dogs. In CBTD dogs, no significant differences in vitamin concentrations considering ultrasound severity were found. Presence of biliary disease in dogs results in lower blood vitamins D and E, and higher vitamin A concentration. Lower vitamins D and E concentration could reflect a possible lipid malabsorption. The higher concentration of vitamin A could be in line with recent human studies, where retinol increases as an expression of dysregulated homeostasis during chronic liver disease.

11 September 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
VHVerena Habermaass
Verena Habermaass
ACAurora Cogozzo
Aurora Cogozzo
FBFrancesco Bartoli
Francesco Bartoli
VVValentina Vitelli
Valentina Vitelli
Rebecca DiniRebecca Dini
Rebecca Dini
Veronica MarchettiVeronica Marchetti
Veronica Marchetti
Background: Water-soluble vitamin deficiencies are common in human chronic liver disease (CLD) due to impaired metabolic pathways. Vitamins B2 (riboflavin), B3 (niacin), and B5 (pantothenic acid) assume critical roles in hepatic and lipid metabolism and may exert hepatoprotective effects. In canine CLD, data beyond cobalamin are sparse, and no guidelines currently endorse B-vitamin supplementation. Methods: This case–control study analysed 66 stored serum samples from client-owned dogs with CLD and 50 from healthy blood-donor dogs. CLD diagnosis required persistent (>2 months) elevation of at least two liver enzymes (ALP, GGT, AST, ALT) and ultrasonographic evidence of CLD. Serum vitamin concentrations were quantified by LC-MS/MS (ng/mL). Results: Vitamin B2 was significantly lower in CLD dogs versus controls (median 48.4 vs. 85.5 ng/mL; p = 0.002). No significant difference was observed in B3 levels (p = 0.25). Vitamin B5 concentrations were significantly higher in the CLD group (median 176.5 vs. 116.1 ng/mL; p = 0.003). Conclusions: Reduced B2 may reflect impaired hepatic processing or absorption in canine CLD. The presence of normal or elevated B3 and B5 may relate to alternative metabolic pathways. This constitutes the first study assessing B2, B3, and B5 in canine CLD, underscoring riboflavin’s potential interest in CLD dogs.